Labetalol
Labetalol, Normozide, Trandate (labetalol) is a small molecule pharmaceutical. Labetalol was first approved as Trandate on 1984-08-01. It is used to treat angina pectoris, heart failure, malignant hypertension, and myocardial infarction in the USA. The pharmaceutical is active against alpha-1D adrenergic receptor, beta-2 adrenergic receptor, and beta-1 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrochlorothiazide
+
Labetalol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRANDATE HCT | GSK | N-019174 DISCN | 1987-04-10 | 4 products |
| NORMOZIDE | Merck & Co | N-019046 DISCN | 1987-04-06 | 4 products |
Hide discontinued
Labetalol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LABETALOL HYDROCHLORIDE | Hikma Pharmaceuticals | N-213330 RX | 2022-03-18 | 1 products, RLD, RS |
| LABETALOL HYDROCHLORIDE IN DEXTROSE | Hikma Pharmaceuticals | N-213330 RX | 2020-11-09 | 1 products, RLD, RS |
| LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE | Hikma Pharmaceuticals | N-213330 RX | 2020-11-09 | 3 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| labetalol hcl in dextrose labetalol hcl in sodium chloride | New Drug Application | 2020-12-21 |
| trandate | New Drug Application | 2009-12-14 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AG: Alpha and beta blocking agents
— C07AG01: Labetalol
— C07B: Beta blocking agents and thiazides
— C07BG: Alpha and beta blocking agents and thiazides
— C07BG01: Labetalol and thiazides
— C07C: Beta blocking agents and other diuretics
— C07CG: Alpha and beta blocking agents and other diuretics
— C07CG01: Labetalol and other diuretics
HCPCS
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 3 | 3 | 2 | 5 | 4 | 15 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 2 | 3 | 2 | 7 | 14 |
| Pregnancy-induced hypertension | D046110 | — | O13 | — | 2 | 3 | 6 | 1 | 11 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 3 | 2 | 5 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 4 | — | 4 |
| Ischemic stroke | D000083242 | — | — | — | 1 | 1 | 2 | — | 4 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | 1 | 1 | 2 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 2 | — | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 2 | — | 2 |
| Laparoscopy | D010535 | — | — | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral hemorrhage | D002543 | — | — | — | 2 | 1 | — | 2 | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 3 | — | — | 2 | 5 |
| Blood pressure | D001794 | EFO_0004325 | — | — | 3 | — | — | — | 3 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | 1 | 1 | — | — | — | 1 |
| Heart rate | D006339 | EFO_0004326 | — | — | 1 | — | — | — | 1 |
| Proteinuria | D011507 | HP_0000093 | R80 | 1 | 1 | — | — | — | 1 |
| Craniotomy | D003399 | — | — | 1 | 1 | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | — | — | 1 |
| Tobacco use disorder | D014029 | — | F17 | — | 1 | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 2 | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 2 | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 2 | 2 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 2 | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 2 | 2 |
| Hypokalemia | D007008 | HP_0002900 | E87.6 | — | — | — | — | 2 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 2 | 2 |
Show 55 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Labetalol |
| INN | labetalol |
| Description | Labetalol is a diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure. It has a role as an antihypertensive agent, a sympatholytic agent, an alpha-adrenergic antagonist and a beta-adrenergic antagonist. It contains a (R,R)-labetalol, a (S,S)-labetalol, a (R,S)-labetolol and a (S,R)-labetolol. |
| Classification | Small molecule |
| Drug class | combined alpha and beta blockers |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 36894-69-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL429 |
| ChEBI ID | 6343 |
| PubChem CID | 3869 |
| DrugBank | DB00598 |
| UNII ID | R5H8897N95 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1D
ADRA1D
ADRB2
ADRB2
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (Q61619)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Labetalol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,652 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,653 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use